JP2018532736A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018532736A5 JP2018532736A5 JP2018519039A JP2018519039A JP2018532736A5 JP 2018532736 A5 JP2018532736 A5 JP 2018532736A5 JP 2018519039 A JP2018519039 A JP 2018519039A JP 2018519039 A JP2018519039 A JP 2018519039A JP 2018532736 A5 JP2018532736 A5 JP 2018532736A5
- Authority
- JP
- Japan
- Prior art keywords
- neoepitope
- matched
- hla
- patient
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562240494P | 2015-10-12 | 2015-10-12 | |
| US62/240,494 | 2015-10-12 | ||
| PCT/US2016/056692 WO2017066357A1 (en) | 2015-10-12 | 2016-10-12 | Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018532736A JP2018532736A (ja) | 2018-11-08 |
| JP2018532736A5 true JP2018532736A5 (https=) | 2019-01-17 |
Family
ID=57882841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519039A Pending JP2018532736A (ja) | 2015-10-12 | 2016-10-12 | チェックポイント阻害物質への感受性を予測するｍｓｉおよびネオエピトープの探索のための系、組成物、および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11626187B2 (https=) |
| EP (1) | EP3362930A4 (https=) |
| JP (1) | JP2018532736A (https=) |
| KR (1) | KR20180087244A (https=) |
| CN (1) | CN108701173A (https=) |
| AU (1) | AU2016339035A1 (https=) |
| CA (1) | CA3003251A1 (https=) |
| HK (1) | HK1258091A1 (https=) |
| IL (1) | IL258679A (https=) |
| WO (1) | WO2017066357A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190099475A1 (en) | 2015-04-08 | 2019-04-04 | Nantomics, Llc | Cancer neoepitopes |
| CA3003251A1 (en) | 2015-10-12 | 2017-04-20 | Nantomics, Llc | Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors |
| CA3014252A1 (en) | 2016-02-12 | 2017-08-17 | Nantomics, Llc | High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies |
| EP3500966B1 (en) | 2016-08-25 | 2021-04-21 | Nantomics, LLC | Immunotherapy markers and uses therefor |
| MA47678A (fr) * | 2017-03-03 | 2021-05-26 | Treos Bio Ltd | Plateforme personnalisée d'identification de peptide immunogène |
| CN111373050A (zh) * | 2017-06-20 | 2020-07-03 | 生物辐射实验室股份有限公司 | 用于遗传不稳定性的数字扩增试验 |
| CN110997903B (zh) * | 2017-08-10 | 2024-03-29 | 古德T细胞有限公司 | 用于癌症治疗的t细胞的活化方法 |
| WO2019041045A1 (en) | 2017-09-01 | 2019-03-07 | The Hospital For Sick Children | PROFILING AND TREATMENT OF HYPERMUTANT CANCER |
| US20200385815A1 (en) * | 2017-12-20 | 2020-12-10 | Nantomics, Llc | Using cfRNA for Diagnosing Minimal Residual Disease |
| EP3784802A1 (en) * | 2018-04-25 | 2021-03-03 | Koninklijke Philips N.V. | Tumor functional mutation and epitope loads as improved predictive biomarkers for immunotherapy response |
| CA3106562A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Off-the-shelf cancer vaccines |
| WO2020022899A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for breast cancer |
| US20210189505A1 (en) * | 2018-08-23 | 2021-06-24 | Nantcell, Inc. | Assessing microsatellite instability by liquid biopsy |
| KR20210086612A (ko) | 2018-09-04 | 2021-07-08 | 트레오스 바이오 리미티드 | 펩타이드 백신 |
| WO2020091944A1 (en) * | 2018-10-31 | 2020-05-07 | Nantomics, Llc | Genomic and immune infiltration differences between msi and mss gi tumors |
| CN110556164B (zh) * | 2019-09-09 | 2023-02-07 | 深圳裕策生物科技有限公司 | 用于目标区域捕获测序检测msi的方法、装置和存储介质 |
| CN110910957B (zh) * | 2019-12-31 | 2023-06-27 | 求臻医学科技(浙江)有限公司 | 一种基于单肿瘤样本高通量测序微卫星不稳定性探测位点筛选方法 |
| CN111785324B (zh) * | 2020-07-02 | 2021-02-02 | 深圳市海普洛斯生物科技有限公司 | 一种微卫星不稳定分析方法及装置 |
| CN112183557A (zh) * | 2020-09-29 | 2021-01-05 | 山西医科大学 | 基于胃癌组织病理图像纹理特征的msi预测模型构建方法 |
| CN114974420A (zh) * | 2021-10-29 | 2022-08-30 | 无锡臻和生物科技有限公司 | 预测胃肠肿瘤免疫检查点抑制剂疗效的标志物及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1639185A (zh) | 2002-01-03 | 2005-07-13 | 斯克里普斯研究学院 | 癌相关表位 |
| CA2518569C (en) | 2003-03-10 | 2011-11-15 | Expression Pathology, Inc. | Liquid tissue preparation from histopathologically processed biological samples, tissues and cells |
| US8207315B2 (en) | 2003-08-20 | 2012-06-26 | The Cleveland Clinic Foundation | Gene and protein associated with angiogenesis and endothelial cell-specific apoptosis |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| WO2006040322A1 (en) | 2004-10-12 | 2006-04-20 | Crucell Holland B.V. | Binding molecules for treatment and detection of cancer |
| WO2007002811A2 (en) | 2005-06-29 | 2007-01-04 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating melanoma |
| KR20120017469A (ko) | 2007-01-05 | 2012-02-28 | 유니버시티 오브 취리히 | 질환 특이적 결합 분자 및 표적을 제공하는 방법 |
| BR112012029066A2 (pt) * | 2010-05-14 | 2020-09-01 | The General Hospital Corporation | composições e processos de identificação de neoantígenos específicos de tumor. |
| EP3657507A1 (en) | 2010-05-25 | 2020-05-27 | The Regents of The University of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
| US9646134B2 (en) | 2010-05-25 | 2017-05-09 | The Regents Of The University Of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| US10501801B2 (en) | 2012-09-28 | 2019-12-10 | University Of Connecticut | Identification of tumor-protective epitopes for the treatment of cancers |
| CN118750591A (zh) | 2013-04-07 | 2024-10-11 | 博德研究所 | 用于个性化瘤形成疫苗的组合物和方法 |
| US20160258025A1 (en) | 2013-10-18 | 2016-09-08 | The Regents Of The University Of California | Predicting patient responsiveness to immune checkpoint inhibitors |
| EP3082853A2 (en) | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| PE20161344A1 (es) * | 2014-01-02 | 2016-12-23 | Memorial Sloan Kettering Cancer Center | Determinantes de respuesta del cancer a la inmunoterapia |
| US20190099475A1 (en) | 2015-04-08 | 2019-04-04 | Nantomics, Llc | Cancer neoepitopes |
| CA2988388C (en) | 2015-04-23 | 2022-11-22 | Nantomics, Llc | Cancer neoepitopes |
| US11393557B2 (en) | 2015-08-25 | 2022-07-19 | Nantomics, Llc | Systems and methods for high-accuracy variant calling |
| CA3003251A1 (en) | 2015-10-12 | 2017-04-20 | Nantomics, Llc | Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors |
-
2016
- 2016-10-12 CA CA3003251A patent/CA3003251A1/en active Pending
- 2016-10-12 JP JP2018519039A patent/JP2018532736A/ja active Pending
- 2016-10-12 AU AU2016339035A patent/AU2016339035A1/en not_active Abandoned
- 2016-10-12 EP EP16856134.8A patent/EP3362930A4/en not_active Withdrawn
- 2016-10-12 KR KR1020187013060A patent/KR20180087244A/ko not_active Withdrawn
- 2016-10-12 CN CN201680065549.6A patent/CN108701173A/zh not_active Withdrawn
- 2016-10-12 HK HK19100475.3A patent/HK1258091A1/zh unknown
- 2016-10-12 US US15/292,021 patent/US11626187B2/en active Active
- 2016-10-12 WO PCT/US2016/056692 patent/WO2017066357A1/en not_active Ceased
-
2018
- 2018-04-12 IL IL258679A patent/IL258679A/en unknown
-
2023
- 2023-02-02 US US18/163,664 patent/US20230307090A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018532736A5 (https=) | ||
| Bolton et al. | Noncoding RNAs in prostate cancer: the long and the short of it | |
| TWI642786B (zh) | 與癌症有關之基因或分子變異之檢測 | |
| US20230335219A1 (en) | Methods and systems for detecting insertions and deletions | |
| JP2018510657A5 (https=) | ||
| Espinosa‐Parrilla et al. | Genetic association of gastric cancer with miRNA clusters including the cancer‐related genes MIR29, MIR25, MIR93 and MIR106: results from the EPIC‐EURGAST study | |
| JP2019512014A (ja) | がん診断法および治療法におけるｐｉＲＮＡを使用する組成物および方法 | |
| JP2019517781A5 (https=) | ||
| Plieskatt et al. | A microRNA profile associated with Opisthorchis viverrini-induced cholangiocarcinoma in tissue and plasma | |
| JP2018532736A (ja) | チェックポイント阻害物質への感受性を予測するｍｓｉおよびネオエピトープの探索のための系、組成物、および方法 | |
| Murphy et al. | Length variations within the Merle retrotransposon of canine PMEL: correlating genotype with phenotype | |
| Guo et al. | Exome sequencing identifies a COL14A1 mutation in a large Chinese pedigree with punctate palmoplantar keratoderma | |
| FI3774897T3 (fi) | Menetelmiä ja järjestelmiä tulehdustautisten potilaiden valintaan ja hoitoon | |
| Omrane et al. | Significant association between IL23R and IL17F polymorphisms and clinical features of colorectal cancer | |
| Wang et al. | Identification of two disease-causing genes TJP2 and GJB2 in a Chinese family with unconditional autosomal dominant nonsyndromic hereditary hearing impairment | |
| KR102238912B1 (ko) | Dna 메틸화 변이 및 종양 변이 부담을 이용한 면역항암치료 반응성 예측방법 | |
| Sakthianandeswaren et al. | Fine mapping of Leishmania major susceptibility Locus lmr2 and evidence of a role for Fli1 in disease and wound healing | |
| CN110462063A (zh) | 一种基于测序数据的变异检测方法、装置和存储介质 | |
| ATE446385T1 (de) | Polymorphismen im nod2/card15 gen | |
| JP2014535050A5 (https=) | ||
| Liu et al. | A pan-genome framework reveals structural variation and small RNA regulation underlying heterodichogamy in Pterocarya | |
| Rosani et al. | Target capture and massive sequencing of genes transcribed in Mytilus galloprovincialis | |
| EP2576816A4 (en) | METHOD AND KIT FOR THE DISTINCTION BETWEEN BREAST CANCER AND A GOOD BREAST DISEASE | |
| Gillespie et al. | Genomic modifiers of natural killer cells, immune responsiveness and lymphoid tissue remodeling together increase host resistance to viral infection | |
| de Deus et al. | Influence of IL10 (G1082A) and TNFα (G308A) polymorphisms on the survival of pediatric patients with ALL |